•
Mar 31, 2024

Elevance Health Q1 2024 Earnings Report

Elevance Health's first quarter results reflected disciplined execution of strategic initiatives, progress in expanding Carelon's capabilities, and increased outlook for full year earnings.

Key Takeaways

Elevance Health reported a 0.9% increase in operating revenue to $42.3 billion for Q1 2024, with diluted EPS up 15.5% to $9.59 and adjusted diluted EPS up 12.5% to $10.64. The company has raised its full-year earnings guidance and is launching a strategic partnership to advance primary care and physician enablement.

Operating revenue increased by 0.9% to $42.3 billion in Q1 2024.

Diluted EPS increased by 15.5% to $9.59, and adjusted diluted EPS increased by 12.5% to $10.64.

Full year diluted EPS and adjusted diluted EPS guidance were raised to greater than $34.05 and $37.20, respectively.

A strategic partnership was launched to advance primary care and physician enablement.

Total Revenue
$42.3B
Previous year: $41.9B
+0.9%
EPS
$10.6
Previous year: $9.46
+12.5%
Total Medical Membership
46.24M
Previous year: 48.1M
-3.9%
Gross Profit
$38.8B
Previous year: $38.7B
+0.2%
Cash and Equivalents
$6.23B
Previous year: $10.1B
-38.6%
Free Cash Flow
$1.7B
Previous year: $6.17B
-72.5%
Total Assets
$112B
Previous year: $109B
+2.6%

Elevance Health

Elevance Health

Forward Guidance

Elevance Health expects net income per diluted share to be greater than $34.05 in 2024 and adjusted diluted net income per share to be greater than $37.20.

Positive Outlook

  • Increased outlook for full year earnings.
  • Strategic partnership to advance primary care and physician enablement.
  • Growth in Carelon's capabilities.
  • Disciplined execution of strategic initiatives.
  • Solid start to the year.